These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
552 related articles for article (PubMed ID: 31854063)
1. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063 [TBL] [Abstract][Full Text] [Related]
2. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824 [TBL] [Abstract][Full Text] [Related]
4. Mutational landscape of inflammatory breast cancer. Bertucci F; Lerebours F; Ceccarelli M; Guille A; Syed N; Finetti P; Adélaïde J; Van Laere S; Goncalves A; Viens P; Birnbaum D; Mamessier E; Callens C; Bedognetti D J Transl Med; 2024 Apr; 22(1):374. PubMed ID: 38637846 [TBL] [Abstract][Full Text] [Related]
5. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453 [TBL] [Abstract][Full Text] [Related]
6. Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. Li X; Kumar S; Harmanci A; Li S; Kitchen RR; Zhang Y; Wali VB; Reddy SM; Woodward WA; Reuben JM; Rozowsky J; Hatzis C; Ueno NT; Krishnamurthy S; Pusztai L; Gerstein M Genome Med; 2021 Apr; 13(1):70. PubMed ID: 33902690 [TBL] [Abstract][Full Text] [Related]
7. High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. Bekhouche I; Finetti P; Adelaïde J; Ferrari A; Tarpin C; Charafe-Jauffret E; Charpin C; Houvenaeghel G; Jacquemier J; Bidaut G; Birnbaum D; Viens P; Chaffanet M; Bertucci F PLoS One; 2011 Feb; 6(2):e16950. PubMed ID: 21339811 [TBL] [Abstract][Full Text] [Related]
8. The Genomic Landscape of Male Breast Cancers. Piscuoglio S; Ng CK; Murray MP; Guerini-Rocco E; Martelotto LG; Geyer FC; Bidard FC; Berman S; Fusco N; Sakr RA; Eberle CA; De Mattos-Arruda L; Macedo GS; Akram M; Baslan T; Hicks JB; King TA; Brogi E; Norton L; Weigelt B; Hudis CA; Reis-Filho JS Clin Cancer Res; 2016 Aug; 22(16):4045-56. PubMed ID: 26960396 [TBL] [Abstract][Full Text] [Related]
9. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958 [TBL] [Abstract][Full Text] [Related]
10. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses. Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724 [TBL] [Abstract][Full Text] [Related]
11. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. Hamm CA; Moran D; Rao K; Trusk PB; Pry K; Sausen M; Jones S; Velculescu VE; Cristofanilli M; Bacus S Mol Cancer Ther; 2016 Jul; 15(7):1746-56. PubMed ID: 27196778 [TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program. Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761 [TBL] [Abstract][Full Text] [Related]
13. Comparative genomic analysis of primary tumors and metastases in breast cancer. Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268 [TBL] [Abstract][Full Text] [Related]
15. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer. Chen SH; Tse KP; Lu YJ; Chen SJ; Tian YF; Tan KT; Li CF Cancer Med; 2024 Jun; 13(12):e7384. PubMed ID: 38895905 [TBL] [Abstract][Full Text] [Related]
17. Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC). Gong Y; Nagarathinam R; Arisi MF; Gerratana L; Winn JS; Slifker M; Pei J; Cai KQ; Hasse Z; Obeid E; Noriega J; Sebastiano C; Ross E; Alpaugh K; Cristofanilli M; Fernandez SV Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445631 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive molecular profiling broadens treatment options for breast cancer patients. Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848 [TBL] [Abstract][Full Text] [Related]
19. Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes. Kadamkulam Syriac A; Nandu NS; Clark A; Tavallai M; Jin DX; Sokol E; McGregor K; Ross JS; Danziger N; Leone JP Breast Cancer Res; 2024 Jul; 26(1):118. PubMed ID: 39049124 [TBL] [Abstract][Full Text] [Related]
20. Clinicogenomic characterization of inflammatory breast cancer. Priedigkeit N; Harrison B; Shue R; Hughes M; Li Y; Kirkner GJ; Spurr LF; Remolano MC; Strauss S; Files J; Feeney AM; Grant L; Mohammed-Abreu A; Garrido-Castro A; Sousa RB; Bychkovsky B; Nakhlis F; Bellon JR; King TA; Winer EP; Lindeman N; Johnson BE; Sholl L; Dillon D; Overmoyer B; Tolaney SM; Cherniack A; Lin NU; Lynce F bioRxiv; 2024 May; ():. PubMed ID: 38766070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]